A. Baldwin

Molecular Biology · Molecular and Cellular Biology · 1999–2008

A researcher in the Science corpus: 10 papers; trusts 4 researchers and is trusted by 21 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 31 citations into it; #3,358 of 17,773 by trust here, #4,273 by citations
• Cancer Research — 13 citations into it; #164 of 1,780 by trust here, #370 by citations
• Oncology — 8 citations into it; #216 of 1,698 by trust here, #729 by citations

Whom A. Baldwin trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Yumi Yamamoto
2. D. Guttridge

Who trusts A. Baldwin overall

1. J. Adams
2. S. Saccani
3. M. Soengas
4. D. Longley
5. Yumi Yamamoto
6. Ricky W. Johnstone
7. M. Karin
8. S. Ghosh
9. Scott W. Lowe
10. Jamie E. Hoberg

Papers from A. Baldwin's perspective

Ordered by how strongly the researchers A. Baldwin trusts endorse each paper. Same corpus, a different order for every researcher.

1. Upstream and downstream of mTOR. (Genes & Development)
2. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. (Cell)
3. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression (Oncogene)
4. Ras, PI(3)K and mTOR signalling controls tumour cell growth (Nature)
5. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR (Proceedings of the National Academy of Sciences of the United States of America)
6. AKT/PKB signaling: navigating downstream. (Cell)
7. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling (Nature Cell Biology)
8. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways (Nature Medicine)
9. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer (Nature Medicine)
10. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (Cancer Research)

Their papers

• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB (2001) — 1,432 citations
• The p65 (RelA) Subunit of NF-κB Interacts with the Histone Deacetylase (HDAC) Corepressors HDAC1 and HDAC2 To Negatively Regulate Gene Expression (2001) — 781 citations
• Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. (2008) — 668 citations
• NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. (2000) — 986 citations
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. (2002) — 765 citations
• A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression (2003) — 444 citations
• Series Introduction: The transcription factor NF-κB and human disease (2001) — 917 citations
• Akt Stimulates the Transactivation Potential of the RelA/p65 Subunit of NF-κB through Utilization of the IκB Kinase and Activation of the Mitogen-activated Protein Kinase p38* (2001) — 857 citations
• Akt Suppresses Apoptosis by Stimulating the Transactivation Potential of the RelA/p65 Subunit of NF-κB (2000) — 701 citations
• A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. (1999)